Filtered By:
Source: Advances in Cancer Research
Cancer: Hepatocellular Carcinoma
This page shows you your search results in order of date.
Order by Relevance | Date
Total 807 results found since Jan 2013.
Beyond glyco-proteomics-Understanding the role of genetics in cancer biomarkers
Adv Cancer Res. 2023;157:57-81. doi: 10.1016/bs.acr.2022.07.002. Epub 2022 Oct 1.ABSTRACTThe development of robust cancer biomarkers is the most effective way to improve overall survival, as early detection and treatment leads to significantly better clinical outcomes. Many of the cancer biomarkers that have been identified and are clinically utilized are glycoproteins, oftentimes a specific glycoform. Aberrant glycosylation is a common theme in cancer, with dysregulated glycosylation driving tumor initiation and metastasis, and abnormal glycosylation can be detection both on the tissue surface and in serum. However, most ...
Source: Advances in Cancer Research - February 1, 2023 Category: Cancer & Oncology Authors: Andrew DelaCourt Anand Mehta Source Type: research
Mass spectrometry based biomarkers for early detection of HCC using a glycoproteomic approach
Adv Cancer Res. 2023;157:23-56. doi: 10.1016/bs.acr.2022.07.005. Epub 2022 Sep 6.ABSTRACTHepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related mortality worldwide and 80%-90% of HCC develops in patients that have underlying cirrhosis. Better methods of surveillance are needed to increase early detection of HCC and the proportion of patients that can be offered curative therapies. Recent work in novel mass spec-based methods for glycomic and glycopeptide analysis for discovery and confirmation of markers for early detection of HCC versus cirrhosis is reviewed in this chapter. Results from recent w...
Source: Advances in Cancer Research - February 1, 2023 Category: Cancer & Oncology Authors: Yehia Mechref Wenjing Peng Sakshi Gautam Parisa Ahmadi Yu Lin Jianhui Zhu Jie Zhang Suyu Liu Amit G Singal Neehar D Parikh David M Lubman Source Type: research
Beyond glyco-proteomics-Understanding the role of genetics in cancer biomarkers
Adv Cancer Res. 2023;157:57-81. doi: 10.1016/bs.acr.2022.07.002. Epub 2022 Oct 1.ABSTRACTThe development of robust cancer biomarkers is the most effective way to improve overall survival, as early detection and treatment leads to significantly better clinical outcomes. Many of the cancer biomarkers that have been identified and are clinically utilized are glycoproteins, oftentimes a specific glycoform. Aberrant glycosylation is a common theme in cancer, with dysregulated glycosylation driving tumor initiation and metastasis, and abnormal glycosylation can be detection both on the tissue surface and in serum. However, most ...
Source: Advances in Cancer Research - February 1, 2023 Category: Cancer & Oncology Authors: Andrew DelaCourt Anand Mehta Source Type: research
Mass spectrometry based biomarkers for early detection of HCC using a glycoproteomic approach
Adv Cancer Res. 2023;157:23-56. doi: 10.1016/bs.acr.2022.07.005. Epub 2022 Sep 6.ABSTRACTHepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related mortality worldwide and 80%-90% of HCC develops in patients that have underlying cirrhosis. Better methods of surveillance are needed to increase early detection of HCC and the proportion of patients that can be offered curative therapies. Recent work in novel mass spec-based methods for glycomic and glycopeptide analysis for discovery and confirmation of markers for early detection of HCC versus cirrhosis is reviewed in this chapter. Results from recent w...
Source: Advances in Cancer Research - February 1, 2023 Category: Cancer & Oncology Authors: Yehia Mechref Wenjing Peng Sakshi Gautam Parisa Ahmadi Yu Lin Jianhui Zhu Jie Zhang Suyu Liu Amit G Singal Neehar D Parikh David M Lubman Source Type: research
Beyond glyco-proteomics-Understanding the role of genetics in cancer biomarkers
Adv Cancer Res. 2023;157:57-81. doi: 10.1016/bs.acr.2022.07.002. Epub 2022 Oct 1.ABSTRACTThe development of robust cancer biomarkers is the most effective way to improve overall survival, as early detection and treatment leads to significantly better clinical outcomes. Many of the cancer biomarkers that have been identified and are clinically utilized are glycoproteins, oftentimes a specific glycoform. Aberrant glycosylation is a common theme in cancer, with dysregulated glycosylation driving tumor initiation and metastasis, and abnormal glycosylation can be detection both on the tissue surface and in serum. However, most ...
Source: Advances in Cancer Research - February 1, 2023 Category: Cancer & Oncology Authors: Andrew DelaCourt Anand Mehta Source Type: research
Mass spectrometry based biomarkers for early detection of HCC using a glycoproteomic approach
Adv Cancer Res. 2023;157:23-56. doi: 10.1016/bs.acr.2022.07.005. Epub 2022 Sep 6.ABSTRACTHepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related mortality worldwide and 80%-90% of HCC develops in patients that have underlying cirrhosis. Better methods of surveillance are needed to increase early detection of HCC and the proportion of patients that can be offered curative therapies. Recent work in novel mass spec-based methods for glycomic and glycopeptide analysis for discovery and confirmation of markers for early detection of HCC versus cirrhosis is reviewed in this chapter. Results from recent w...
Source: Advances in Cancer Research - February 1, 2023 Category: Cancer & Oncology Authors: Yehia Mechref Wenjing Peng Sakshi Gautam Parisa Ahmadi Yu Lin Jianhui Zhu Jie Zhang Suyu Liu Amit G Singal Neehar D Parikh David M Lubman Source Type: research
Beyond glyco-proteomics-Understanding the role of genetics in cancer biomarkers
Adv Cancer Res. 2023;157:57-81. doi: 10.1016/bs.acr.2022.07.002. Epub 2022 Oct 1.ABSTRACTThe development of robust cancer biomarkers is the most effective way to improve overall survival, as early detection and treatment leads to significantly better clinical outcomes. Many of the cancer biomarkers that have been identified and are clinically utilized are glycoproteins, oftentimes a specific glycoform. Aberrant glycosylation is a common theme in cancer, with dysregulated glycosylation driving tumor initiation and metastasis, and abnormal glycosylation can be detection both on the tissue surface and in serum. However, most ...
Source: Advances in Cancer Research - February 1, 2023 Category: Cancer & Oncology Authors: Andrew DelaCourt Anand Mehta Source Type: research
Mass spectrometry based biomarkers for early detection of HCC using a glycoproteomic approach
Adv Cancer Res. 2023;157:23-56. doi: 10.1016/bs.acr.2022.07.005. Epub 2022 Sep 6.ABSTRACTHepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related mortality worldwide and 80%-90% of HCC develops in patients that have underlying cirrhosis. Better methods of surveillance are needed to increase early detection of HCC and the proportion of patients that can be offered curative therapies. Recent work in novel mass spec-based methods for glycomic and glycopeptide analysis for discovery and confirmation of markers for early detection of HCC versus cirrhosis is reviewed in this chapter. Results from recent w...
Source: Advances in Cancer Research - February 1, 2023 Category: Cancer & Oncology Authors: Yehia Mechref Wenjing Peng Sakshi Gautam Parisa Ahmadi Yu Lin Jianhui Zhu Jie Zhang Suyu Liu Amit G Singal Neehar D Parikh David M Lubman Source Type: research
Beyond glyco-proteomics-Understanding the role of genetics in cancer biomarkers
Adv Cancer Res. 2023;157:57-81. doi: 10.1016/bs.acr.2022.07.002. Epub 2022 Oct 1.ABSTRACTThe development of robust cancer biomarkers is the most effective way to improve overall survival, as early detection and treatment leads to significantly better clinical outcomes. Many of the cancer biomarkers that have been identified and are clinically utilized are glycoproteins, oftentimes a specific glycoform. Aberrant glycosylation is a common theme in cancer, with dysregulated glycosylation driving tumor initiation and metastasis, and abnormal glycosylation can be detection both on the tissue surface and in serum. However, most ...
Source: Advances in Cancer Research - February 1, 2023 Category: Cancer & Oncology Authors: Andrew DelaCourt Anand Mehta Source Type: research
Mass spectrometry based biomarkers for early detection of HCC using a glycoproteomic approach
Adv Cancer Res. 2023;157:23-56. doi: 10.1016/bs.acr.2022.07.005. Epub 2022 Sep 6.ABSTRACTHepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related mortality worldwide and 80%-90% of HCC develops in patients that have underlying cirrhosis. Better methods of surveillance are needed to increase early detection of HCC and the proportion of patients that can be offered curative therapies. Recent work in novel mass spec-based methods for glycomic and glycopeptide analysis for discovery and confirmation of markers for early detection of HCC versus cirrhosis is reviewed in this chapter. Results from recent w...
Source: Advances in Cancer Research - February 1, 2023 Category: Cancer & Oncology Authors: Yehia Mechref Wenjing Peng Sakshi Gautam Parisa Ahmadi Yu Lin Jianhui Zhu Jie Zhang Suyu Liu Amit G Singal Neehar D Parikh David M Lubman Source Type: research
Beyond glyco-proteomics-Understanding the role of genetics in cancer biomarkers
Adv Cancer Res. 2023;157:57-81. doi: 10.1016/bs.acr.2022.07.002. Epub 2022 Oct 1.ABSTRACTThe development of robust cancer biomarkers is the most effective way to improve overall survival, as early detection and treatment leads to significantly better clinical outcomes. Many of the cancer biomarkers that have been identified and are clinically utilized are glycoproteins, oftentimes a specific glycoform. Aberrant glycosylation is a common theme in cancer, with dysregulated glycosylation driving tumor initiation and metastasis, and abnormal glycosylation can be detection both on the tissue surface and in serum. However, most ...
Source: Advances in Cancer Research - February 1, 2023 Category: Cancer & Oncology Authors: Andrew DelaCourt Anand Mehta Source Type: research
Mass spectrometry based biomarkers for early detection of HCC using a glycoproteomic approach
Adv Cancer Res. 2023;157:23-56. doi: 10.1016/bs.acr.2022.07.005. Epub 2022 Sep 6.ABSTRACTHepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related mortality worldwide and 80%-90% of HCC develops in patients that have underlying cirrhosis. Better methods of surveillance are needed to increase early detection of HCC and the proportion of patients that can be offered curative therapies. Recent work in novel mass spec-based methods for glycomic and glycopeptide analysis for discovery and confirmation of markers for early detection of HCC versus cirrhosis is reviewed in this chapter. Results from recent w...
Source: Advances in Cancer Research - February 1, 2023 Category: Cancer & Oncology Authors: Yehia Mechref Wenjing Peng Sakshi Gautam Parisa Ahmadi Yu Lin Jianhui Zhu Jie Zhang Suyu Liu Amit G Singal Neehar D Parikh David M Lubman Source Type: research
